Contribution of anti-inflammatory/immune suppressive processes to the pathology of sepsis

被引:43
作者
Perl, M [1 ]
Chung, CS [1 ]
Garber, M [1 ]
Huang, X [1 ]
Ayala, A [1 ]
机构
[1] Brown Univ, Sch Med, Rhode Isl Hosp, Dept Surg,Div Surg Rres, Providence, RI 02903 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2006年 / 11卷
关键词
sepsis; systemic infection; mice; human; apoptosis; immune dysfunction; organ dysfunction; review;
D O I
10.2741/1797
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sepsis is the leading cause of death in critically ill patients in the United States. It is associated with enormous expenditures within the health care system and despite substantial human, medical and fiscal resources directed at this clinical entity we have only had a modest effect on the septic patient's long- term survival. However, extensive studies over the last few decades have begun to reveal important pathophysiological processes around which a few promising therapeutic strategies with potential benefits may be derived. It is generally believed, that the body reacts to a septic challenge with an intense hyperinflammatory response, designed to eliminate the underlying pathogen. However, along with and in response to the intense pro- inflammatory reaction, mechanisms fall into place to counter regulate ( control) this initial response, typically resulting in a down regulation of the inflammatory response. This frequently results in dysfunction of various immunological conditions and may result in the inability to ward off the infection and consecutively lead to multiple organ dysfunction, multiple organ failure and death. It is the aberrant development of this anti- inflammatory/ immunosuppressive response, in which it is important to expand our understanding of pathological components to develop potential remedy. Upon this background this review aims to provide an overview on the pathophysiological mechanisms which initiate or maintain the down regulation of the immune response to a septic challenge and which might be a starting point for the development of therapeutic strategies.
引用
收藏
页码:272 / 299
页数:28
相关论文
共 319 条
[1]   EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL [J].
ABRAHAM, E ;
WUNDERINK, R ;
SILVERMAN, H ;
PERL, TM ;
NASRAWAY, S ;
LEVY, H ;
BONE, R ;
WENZEL, RP ;
BALK, R ;
ALLRED, R ;
PENNINGTON, JE ;
WHERRY, JC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (12) :934-941
[2]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[3]   NF-κB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance [J].
Adib-Conquy, M ;
Adrie, C ;
Moine, P ;
Asehnoune, K ;
Fitting, C ;
Pinsky, MR ;
Dhainaut, JF ;
Cavaillon, JM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (05) :1877-1883
[4]   Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-γ [J].
Ajizian, SJ ;
English, BK ;
Meals, EA .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (04) :939-944
[5]   Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study [J].
Alberti, C ;
Brun-Buisson, C ;
Burchardi, H ;
Martin, C ;
Goodman, S ;
Artigas, A ;
Sicignano, A ;
Palazzo, M ;
Moreno, R ;
Boulmé, R ;
Lepage, E ;
Le Gall, JR .
INTENSIVE CARE MEDICINE, 2002, 28 (02) :108-121
[6]   Regulatory T cells: Peace keepers in the gut [J].
Allez, M ;
Mayer, L .
INFLAMMATORY BOWEL DISEASES, 2004, 10 (05) :666-676
[7]  
ANGEL MK, 1998, AM J PHYSIOL, P274
[8]  
Angele MK, 1997, ARCH SURG-CHICAGO, V132, P1207
[9]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[10]   Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock [J].
Annane, D ;
Sébille, V ;
Charpentier, C ;
Bollaert, PE ;
François, B ;
Korach, JM ;
Capellier, G ;
Cohen, Y ;
Azoulay, E ;
Troché, G ;
Chaumet-Riffaut, P ;
Bellissant, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07) :862-871